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Mutations in fukutin-related protein (FKRP) gene cause 
a wide spectrum of disease phenotypes including the 
mild limb-girdle muscular dystrophy 2I (LGMD2I), the 
severe Walker-Warburg syndrome, and muscle-eye-brain 
disease. FKRP deficiency results in α-dystroglycan (α-DG) 
hypoglycosylation in the muscle and heart, which is a 
biochemical hallmark of dystroglycanopathies. To study 
gene replacement therapy, we generated and charac-
terized a new mouse model of LGMD2I harboring the 
human mutation leucine 276 to isoleucine (L276I) in the 
mouse alleles. The homozygous knock-in mice (L276IKI) 
mimic the classic late onset phenotype of LGMD2I in 
both skeletal and cardiac muscles. Systemic delivery of 
human FKRP gene by AAV9 vector in the L276IKI mice, at 
either neonatal age or at the age of 9 months, rendered 
body wide FKRP expression and restored glycosylation 
of α-DG in both skeletal and cardiac muscles. FKRP gene 
therapy ameliorated dystrophic pathology and cardio-
myopathy such as muscle degeneration, fibrosis, and 
myofiber membrane leakage, resulting in restoration 
of muscle and heart contractile functions. Thus, these 
results demonstrated that the treatment based on FKRP 
gene replacement was effective.
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publication 19 August 2014. doi:10.1038/mt.2014.141
INTRODUCTION
Muscular dystrophies (MDs) are a class of hereditary, degenera-
tive disorders of striated muscles. MDs are caused by defects in 
genes that encode a diverse group of proteins.1 Among them, a 
subset of MDs shares the same biochemical feature of reduced 
glycosylation of α-dystroglycan and diminished laminin bind-
ing activity, collectively termed dystroglycanopathies.2 They are a 
heterogeneous group of autosomal recessive diseases with a wide 
spectrum of clinical severities.3,4
Dystroglycan (DG) consists of a heavily glycosylated extracel-
lular α subunit (α-DG) and a transmembrane β subunit (β-DG). 
α-DG and β-DG are encoded by a single gene and post-trans-
lationally cleaved to generate the two subunits.5 α-DG is a cell 
surface receptor for several extracellular matrix proteins such as 
laminin, agrin, and perlecan in muscle,6 and neurexin in brain.7 
The trans-membrane β-DG anchors α-DG at the cell surface and 
binds intracellularly to dystrophin, which in turn binds to the 
actin cytoskeleton. Thus, DG functions as a molecular anchor, 
connecting the extracellular matrix with the cytoskeleton across 
the plasma membrane in skeletal muscle.8 Deficiencies of pro-
teins and enzymes involved in the pathways of α-DG post-trans-
lational modification, e.g., glycosylation, are chiefly responsible 
for dystroglycanopathies. The dystroglycanopathies account for 
the second most common group of MDs, only less frequent than 
Duchenne muscular dystrophy (DMD).9 Currently, more than six 
proteins have been identified in DG glycosylation pathway.10–15 
Specifically, protein O-mannosyltransferase 1 (POMT1), POMT2, 
and protein O-linked mannose N-acetylglucosaminyltransferase 
1 (POMGnT1) are shown to initiate the first two steps of the 
O-mannosylation pathway, a unique type of O-linked glycosyl-
ation in α-DG.16 Fukutin-related protein (FKRP) and LARGE 
(like-acetylglucosaminyltransferase) are involved in phosphoryla-
tion of O-linked mannose in α-DG, which is required for laminin 
binding.5,17
Mutations in the FKRP gene cause a wide spectrum of dis-
ease severity in muscular dystrophies. There is a general gen-
otype–phenotype correlation in patients, despite the fact that 
hypoglycosylation of α-DG can be variable in FKRP associated 
dystroglycanopathy.18 The milder, most common form is limb gir-
dle muscular dystrophy 2I (LGMD2I), characterized by childhood 
or adult onset with a relatively benign disease course.4 Individuals 
with LGMD2I are mostly homozygous for the Leu276Ile (nucleo-
tide C826A) mutation of FKRP and show a variable but appar-
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Duchenne-like severity typically have a moderate reduction in 
α-DG and contain compound heterozygous mutations, includ-
ing the common C826A FKRP mutation and other missense or 
nonsense mutations.18,19 The more severe form is the congenital 
muscular dystrophy type 1C (MDC1C) characterized by early 
onset, inability to walk, and highly elevated serum creatine kinase 
(CK) levels.4 The MDC1C is a compound heterozygote between a 
nonsense and a missense mutation or two missense mutations.18 
The most severe forms of FKRP deficiency containing missense 
mutations are clinically similar to Walker-Warburg syndrome 
(mutation in POMT1 gene) or muscle-eye-brain disease (muta-
tion in POMGnT1 gene), which has striking structural brain 
and eye defects.20 Until recently, the lack of viable animal mod-
els has impeded research in pathogenesis and therapy. Deletion 
of the mouse FKRP gene or homozygous nonsense mutations are 
embryonic lethal.21 To circumvent embryonic lethality, we previ-
ously utilized gene delivery of RNA interference technology to 
knock down FKRP expression, via postnatal gene delivery, cre-
ating a FKRP deficient animal model.22 More recently, the FKRP 
P448L mutation knock-in animal model was generated, which 
resembles clinically severe MDC1C phenotypes with brain and 
eye involvement.21,23
In the current study, a mild LGMD2I animal model is gen-
erated by knocking in the common human L276I mutation, 
producing homozygous mice (L276IKI) that carry this mutation. 
The mouse model has been extensively characterized for their 
phenotypes, which are found to closely recapitulate resemble the 
clinical pathology and phenotypes of the LGMD2I patients. Using 
the L276IKI mice, we have tested adeno-associated virus (AAV)-
mediated gene therapy for the treatment of LGMD2I. AAV vectors 
are highly efficient in transducing skeletal and cardiac muscle cells 
by in vivo gene delivery.24,25 The vectors have been broadly used to 
study other types of muscular dystrophies, such as DMD25–27 and 
laminin-α2 deficient congenital muscular dystrophy.28 Here, we 
have used AAV9 vector to systemically deliver the FKRP gene into 
the neonatal and adult L276IKI mice for long-term gene expres-
sion and therapeutic benefits. We found that overexpression of 
FKRP in both skeletal and cardiac muscle effectively restored the 
biochemical deficiency and normalized glycosylation of α-DG. 
Body wide FKRP gene expression showed no discernable toxicity, 
but prevented the development of dystrophic pathology in mice 
treated neonatally, and effectively ameliorated the pathology in 
mice treated at the adult age. More importantly, overexpression of 
FKRP resulted in contractile function recovery of skeletal muscles 
as well as cardiac muscles. Therefore, due to the lack of any effec-
tive treatment for FKRP deficient patients, the new mouse model 
and FKRP gene transfer study will facilitate our understand-
ing of LGMD2I molecular pathogenesis as well as therapeutic 
developments.21,22
RESULTS
FKRP L276IKI knock-in mice show both muscular 
dystrophy and cardiomyopathy
The LGMD2I mouse model was generated by knocking in the 
human mutation (nucleotide C826 to A) into the coding sequence 
of the mouse FKRP gene, resulting in amino acid replacement 
L276I.21,22 The founder mice were bred to produce homozygous 
FKRP knock-in mice with hybrid 129/C57BL6 background, 
termed hybrid L276IKI line. Additionally, the hybrid line was fur-
ther back-crossed with the syngeneic C57/BL6 mice for more than 
10 generations to produce a genetically homogeneous line, termed 
B6 L276IKI. The growth rate and life span of the homozygous mice 
were indistinguishable from their heterozygous littermates. Both 
hybrid and B6 L276IKI homozygous mice were bred normally.
Both lines of homozygous L276IKI mice displayed late onset of 
mild muscular dystrophic pathology. Muscle histology between 
heterozygous and homozygous mice was minimal at 3 months of 
age (Figure 1a). At 6 months of age, the centrally located nuclei 
(CN) in myofibers started to increase in the homozygous group 
(homo 9.4 ± 1.8% versus hetero 1.4 ± 0.6% in quadriceps, rectus 
femoris, muscle), ultimately reaching ~30% central nucleation in 
mice older than 9 months (Figure 1b). Compared to the severe 
phenotype of the FKRP P448LKI model, the muscle pathology, 
such as fibrosis and cellular infiltration, in FKRP L276IKI mice 
were often focal and not uniform in the same muscle groups. 
However, the degree of myofiber central nucleation and the over-
all interstitial fibrosis increased consistently with age.
The diaphragm of homozygous L276IKI mice was the muscle 
most severely affected, as shown by pronounced membrane leak-
age and fibrosis, especially in the older mice (Figure 1c). These 
results are similar to that of the mdx mice of DMD model.29 
Evans blue dye was injected into 18-month-old heterozygous and 
homozygous mice. Evans blue is a widely used vital red fluores-
cent dye that is taken up by the cells with leaky cell membrane.25 
We found that the diaphragm was the major muscle that took up 
the dye (Figure 1c). Other muscles including tibialis, gastrocne-
mius, quadriceps, and heart had limited dye uptake as shown by 
increased intensity of interstitial red fluorescence (Supplementary 
Figure S1; Figure 1c). Additionally, we observed significant 
increase in fibrosis of the diaphragm, which was revealed by Sirius 
red/fast green staining (Figure 1c). A Sirius red/fast green dye 
staining technique, which binds selectively to collagen and non-
collagen protein, respectively, is a commonly used assay to dis-
play and quantify the amount of collagen deposition occurring 
in the tissues. Quantitative collagen content (an indicator of the 
extent of fibrosis) analysis showed an increase in the diaphragm 
of the homozygous versus heterozygous mice (2.4 ± 0.6% versus 
1.3 ± 0.2%; n = 5, P < 0.05) (Figure 1d). Similarly, heart tissue 
fibrosis also increased in the homozygous B6 L276IKI mice (Figure 
1c), signifying the presence of cardiomyopathy.
Another hallmark of dystrophic pathology in homozygous 
L276IKI mice is elevated serum CK levels, which indicate muscle 
damage.30 While the average serum CK levels in wild-type and het-
erozygous FKRP L276IKI mice were below 300 units/l, all homozy-
gous B6 L276IKI mice (with C57/BL6 background) had CK levels 
greater than 1,000 units/l (Figure 1e). Moreover, a trend emerged 
as the serum CK levels increased with age (Figure 1e), which was 
consistent with the histopathology observations (Figure 1a).
The homozygous L276IKI mice had impaired muscle functions, 
such as shorter treadmill running distance and lower in vitro iso-
metric force production. The running distance of the 9-month-
old hybrid background heterozygous mice was 697 ± 97 meters, 
while the running distance of the age- and sex-matched homo-
zygous L276IKI litter mates was only 353 ± 172 meters (n was 5 in 
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the first group and 9 in the second group, P < 0.01) (Figure 1f). 
The in vitro contraction measurement of the TA muscles showed 
a decrease in the specific isometric tetanic force of the 13-month-
old hybrid homozygous L276IKI mice compared to their heterozy-
gous littermates (23.5 ± 2.5 versus 32.5 ± 4.5 N/cm2, P < 0.05, n = 
5) (Supplementary Figure S2). Unlike the dystrophin-deficient 
mdx mice,31 the L276IKI mice did not show a significant difference 
from its control heterozygous group during the 10-cycle eccen-
tric contraction assay (lengthening activation) (Figure 1g), again 
suggesting mild dystrophic phenotypes. The liver and kidney 
functions of the homozygous mice had no abnormalities as shown 
by blood urea nitrogen (BUN) and serum alanine transaminase 
(ALT) levels (Supplementary Figure S3).
Systemic FKRP gene transfer restored glycosylation of 
α-dystroglycan
Our next step was to investigate the therapeutic intervention by 
systemic gene transfer of FKRP. Mouse codon-optimized FKRP 
gene and the ubiquitous CB promoter (CMV enhancer/chicken 
β-actin promoter) were used for strong and sustained transgene 
Figure 1 Characterization of homozygous FKRP L276IKI mice. (a) Muscle pathology corresponding to age was displayed for both heterozygous 
and B6 L276IKI homozygous mice. Cryo-thin-sections of the quadriceps muscle from different ages were analyzed with H&E staining. Large amount 
of centrally nucleated myofibers were observed in the quadriceps of both the 6- and 9-month-old B6 L276IKI homozygous mice compared to the het-
erozygous mice. (b) Quantitation of centrally nucleated myofibers in homozygous versus heterozygous mice at different ages (n = 8; *P < 0.05; **P < 
0.001). (c) Muscle leakage and fibrosis progression seen in 18 months old homozygous FKRP L276I mice. The diaphragm of homozygous FKRP L276IKI 
mice (18-month-old) displayed the most dramatic dystrophic pathology as revealed by the Evans blue dye leakage, mononuclear cell infiltration (H&E 
staining), and fibrosis infiltration (collagen staining). Sirius red was used to stain collagen (red), and Fast green was utilized for myofiber staining 
(green). (d) Quantification of collagen content in the diaphragm muscle shown in Figure 1c. The collagen content was expressed as a percentage 
of the collagen (Sirius red staining) versus the noncollagen protein (fast green staining). Statistics were calculated by an unpaired t-test with Welch’s 
correction (*P < 0.05; n = 4). (e) The serum creatine kinase level was increased in homozygous mice. All homozygous B6 L276IKI mice had CK levels 
greater than 1,000 units/l, and revealed a trend that the serum CK levels increase with age (*P < 0.05 with one-way analysis of variance (ANOVA); n 
= 4–9). (f) The treadmill running experiment indicated homozygous mice ran shorter distance than heterozygous control (**P = 0.01 with one-way 
ANOVA; n = 5–9). (g) The in vitro eccentric contraction force measurement. There was no difference in force production after 10 cycles of eccentric 
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expression.32 Myc tag was fused to the C-terminus of the FKRP 
coding sequence to facilitate detection. The optimized FKRP gene 
was packaged into AAV9 vector which would efficiently cross the 
blood vessel barrier and transduce whole-body muscle cells after 
systemic delivery.32
First, we delivered the AAV9-CB-FKRP vector into neonatal 
mice to see whether or not overexpression of FKRP can prevent 
muscular dystrophic pathology in early age. AAV9-CB-FKRP-
myc (1 × 1011 vector genomes (vg)/mouse) was injected intraperi-
toneally into 3-day-old homozygous L276IKI mice (with hybrid 
background). At different time points (1 month and 9 months) 
after vector delivery, some of the mice (three from each group) 
were sacrificed for examination of transgene expression and eval-
uation of pathology improvement. Immunofluorescent (IF) stain-
ing against FKRP in cryo-thin-section of muscle tissue displayed 
strong transgene expression in all of the major muscle tissues 
examined (Figure 2a). FKRP expression appeared as punctate 
dots in the cytoplasmic compartment of the myofibers (Figure 
2a), which was previously shown in the Golgi and endoplasmic 
reticulum (ER).23 Also, FKRP expression in skeletal muscles was 
confirmed by western blot (Figure 2b) and anti-myc staining 
(Supplementary Figure S4).
Similar to other dystroglycanopathy animal models,2,21 hypo-
glycosylation of α-DG is a feature of homozygous L276IKI mice. 
To examine if overexpression of FKRP in the skeletal muscle of 
homozygous L276IKI mice would restore the glycosylation of 
α-DG, we performed immunofluorescent staining and western 
blot with the widely used monoclonal antibody IIH6. IIH6 only 
recognizes the functional glycan epitopes of α-DG.2 The homo-
zygous L276IKI skeletal muscle displayed weak or background 
levels of glycosylated α-DG by IF staining (Figure 2c). The weak 
glycosylation signal of α-DG was also revealed by western blot, 
indicating hypoglycosylation of α-DG in the skeletal muscle of 
the homozygous L276IKI mice (Figure 2b). In contrast, the AAV-
CB-FKRP-myc treated homozygous muscle displayed strong 
immunofluorescent signal after IIH6 antibody staining. The gly-
cosylation of α-DG was effectively restored even 12 months after 
vector delivery (Figure 2c), making it indistinguishable from the 
heterozygous controls. These results demonstrated that overex-
pression of FKRP in skeletal muscle via AAV vector delivery fully 
restored the glycosylation of the α-DG in the LGMD2I mouse 
model.
Systemic FKRP gene transfer effectively ameliorates 
muscle pathology
We found that overexpression of FKRP in the homozygous L276IKI 
mice (treated at the neonatal age) was able to normalize muscle 
pathology, as shown by H&E staining (Figure 2d). The AAV9-
CB-FKRP-myc treatment of theL276IKI mice fully prevented 
the formation of centrally located nuclei in the myofibers and 
the mononuclear cell infiltration in the muscles (Figure 2d). As 
expected, the treated mice’s serum CK levels returned to normal 
Figure 2 Improvement of muscle pathology and function after delivery of AAV9-CB-fukutin-related protein (FKRP)-myc vector in neonates. 
The AAV9-CB-FKRP-myc vector (1 × 1011 vg/pup) was delivered into 3-day-old homozygous pups. (a) Overexpression of FKRP on AAV-treated muscle. 
The mice (three per group) were sacrificed 1 month after adeno-associated virus (AAV) treatment, and immunofluorescent staining against FKRP was 
performed on the indicated tissues. ABD, abdominal muscle; Diaph, diaphragm muscle; GAS, gastrocnemius muscle; TA, tibialis muscle. (b) Western 
blot analysis of FKRP expression and glycosylated α-DG expression in quadriceps muscles from indicated mice. A total protein of 15 µg was loaded in 
each lane. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was the loading control here. (c) Hypoglycosylation of α-DG in quadriceps muscles 
from homozygous FKRP L276IKI mice and the restoration of α-DG glycosylation by AAV vector treatment. The insets were large magnification (×40) of 
the same area (rectus femoris quadriceps muscle) (d) Muscle pathology improvement revealed by H&E staining. The mice were sacrificed 9 months 
after treatment for pathology examination. (e) The serum creatine kinase levels were significantly decreased after AAV treatment. (*P < 0.05; n = 5 for 
homo group, and n = 9 for AAV9-CB-FKRP-myc treatment group). (f) Delivery of AAV9-CB-FKRP vector in neonatal mice (C57/BL6 background) also 
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(151 ± 57 units/l) in comparison to their untreated counterparts 
(816 ± 546 units/l, P < 0.05, n = 5–9) (Figure 2e). Furthermore, 
the muscle function improved after gene therapy in the hybrid 
homozygous L276IKI mice. Treadmill tests showed that the treated 
homozygous mice ran much further distances (412.0 ± 53.7 
meters) than their untreated counterparts (299.8 ± 33.7 meters, P 
< 0.001, n = 4–8).
Considering L276IKI mice manifested delayed disease onset, 
we also performed gene therapy in adult homozygous mice, in 
order to examine whether therapeutic effects could be observed 
after the dystrophic pathology already appeared. The AAV9-CB-
FKRP-myc vectors were delivered into 9-month-old homozy-
gous L276IKI mice (which corresponds to a 25-year-old human 
with similar symptoms) at a dosage of 6 × 1013 vg/kg via tail vein 
injection. Three months after vector delivery, three mice from 
each group were sacrificed and their tissues were utilized for 
pathology analysis. As anticipated, the treatment of these older 
mice was also able to efficiently restore the muscle morphology, 
shown by the H&E staining (Figure 3a). The centrally nucleated 
myofibers were significantly decreased in the treated homozygous 
mice (2.98 ± 0.82%) as compared to their untreated homozygous 
counterparts (13.89 ± 4.73%, P < 0.001, n = 3) (Figure 3c). The 
vector treatment ameliorated fibrosis infiltration as revealed by 
Masson’s trichrome staining (Figure 3b). Quantitative data of col-
lagen content failed to show statistical significance (P > 0.05, n = 
5), but did indicate there was a decreasing fibrosis trend (Figure 
3d). The treadmill running experiment demonstrated muscle 
function improvement by the treatment (Figure 3e). The treated 
homozygous mice ran much longer distance than the untreated 
littermates (697 ± 97 m versus 353 ± 172 m), and the running dis-
tance was comparable to the heterozygous controls (673 ± 108 m, 
P < 0.01, n = 5–9). These results indicated that delivering AAV9 
Figure 3 Delivery of AAV vector encoding fukutin-related protein (FKRP) in adult homozygous mice ameliorated dystrophic pathology and 
improved fibrosis infiltration. The AAV9-CB-FKRP vector was delivered into 9-month-old homozygous mice (hybrid background), and the mice 
were sacrificed 3 months after treatment. (a) H&E staining indicated that the skeletal muscle pathology was ameliorated after adeno-associated virus 
(AAV) treatment. Gas, gastrocnemius muscle; TA, tibialis muscle; Quadri, quadriceps (rectus femoris) muscle. (b) Masson’s trichrome staining revealed 
a fibrosis infiltration reduction by the delivery of AAV vector encoding FKRP. (c) Quantification of centrally nucleated myofibers. All of the gastrocne-
mius muscle fibers (a minimum of 267 muscle fibers) were counted on each photo (objective ×10) of H&E staining, and at least three photos were 
included for each mouse. The percentile of centrally nucleated fibers was defined as the percentage of centrally nucleated fibers versus the total 
counted myofibers. The one-way analysis of variance (ANOVA) test was utilized for statistical analysis (**P = 0.0002; three animals were used for each 
group). (d) Quantification of collagen content in Gastrocnemius muscle. This analysis failed to show statistical significance (P = 0.08, n = 5), but did 
indicate there was a decreasing fibrosis trend. (e) Motor function recovery by AAV9-CB-FKRP treatment in older homozygous mice. The vector was 
delivered into 9-month-old male homozygous mice (hybrid background), and the treadmill test was performed 4 months after treatment (**P < 0.01 
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vector encoding FKRP gene could be therapeutic even in older 
homozygous mice that already displayed dystrophic pathology.
Prevention of cardiomyopathy and improvement of 
heart contractile capacity
It has been reported that LGMD2I patients often develop cardio-
myopathy.33 In homozygous FKRP L276IKI mice, focal and scat-
tered fibrosis was also observed in the cardiac muscle (Figure 1c). 
Therefore, we examined if overexpression of FKRP in the heart 
could improve cardiomyopathy. To achieve robust and persistent 
cardiac expression, we utilized an improved cardiac- and skeletal-
muscle specific synthetic promoter,34,35 in addition to the ubiq-
uitous CB promoter. The muscle-specific promoter contained a 
synthetic muscle promoter35 and an 100 bp fragment downstream 
of the +1 site in the chicken skeletal α-actin promoter, which 
was designated as syn100. The AAV9-syn100-FKRP and AAV9-
CB-FKRP vectors were delivered into the neonatal homozygous 
L276IKI mice (3 days old). The untreated littermates were used as 
the control. Seven months after vector delivery, the mice were sub-
jected to echocardiography analysis and subsequently FKRP gene 
expression analysis. AAV9-CB-FKRP and AAV9-syn100-FKRP 
vector rendered strong FKRP expression in both cardiac and 
skeletal muscle as evidence by the IF staining (Figure 4a) and the 
western blot (Figure 4b). Similar to the expression pattern seen 
in skeletal muscle, the expression of FKRP in the heart muscle 
cytoplasm appeared as punctate dots, and the wild-type FKRP in 
heterozygous and homozygous mice could not be detected by the 
anti-FKRP antibody (Figure 4a). As expected, overexpression of 
FKRP by AAV9-syn100-FKRP and AAV9-CB-FKRP in homozy-
gous mice heart restored the glycosylation of α-DG.
Finally, we investigated if gene therapy could improve car-
diac function. Similar to the mdx mice, the FKRP L276IKI mice 
displayed a mild cardiac function deficit, which is not readily 
detectable by regular echocardiography.36 Therefore, we opted to 
evaluate the cardiac function by echocardiography (Echo) with a 
dobutamine challenge. Dobutamine is a sympathomimetic drug 
that stimulates ß1-adrenergic receptors in the heart, resulting in 
an increase in heart rate, contractility and demand for myocardial 
oxygen.37 Clinically, the dobutamine stress test provides a more 
revealing diagnostic and prognostic examination for cardiomy-
opathy patients.37 Echocardiography was performed before and 
2 minutes after dobutamine administration on the 7-month-old 
homozygous, heterozygous, AAV9-syn100-FKRP-treated, and 
AAV9-CB-FKRP-treated homozygous mice.38 Before dobutamine 
stimulation, no significant difference of cardiac systolic func-
tion was found among the four groups of mice as determined 
Figure 4 Restoration of α-DG glycosylation and improvement of cardiac contractile capacity by delivery of adeno-associated virus (AAV)9 
encoding fukutin-related protein (FKRP) gene. The AAV9-syn100-FKRP and AAV9-CB-FKRP vectors (3 × 1011 vg/pup) were delivered into the neo-
natal mice, and age matched heterozygous and homozygous mice were used as controls. Gene expression and heart function examinations were 
performed 7 months after vector delivery. (a) Overexpression of FKRP via AAV vector, driven by muscle-specific syn100 promoter or ubiquitous CB 
promoter, all restored the glycosylation of α-DG in the homozygous FKRP L276IKI mice shown by the IF staining. (b) The western blot further indicated 
that overexpression of FKRP in homozygous mice completely restored the glycosylation of α-DG. For the western blot of FKRP expression, homozy-
gous mice were treated by AAV9-CB-FKRP vector. (c) The dobutamine stress Echo indicated improvement in ejection fraction (EF) for both syn100-
FKRP and CB-FKRP treated groups after dobutamine stimulation. (d) The dobutamine stress Echo displayed enhanced cardiac contractile function in 
fractional shortening (FS) for both syn100-FKRP- and CB-FKRP-treated groups after dobutamine stimulation. (*P < 0.05, n = 3 for treated group, and 
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by ejection fraction (EF) and fractional shortening (FS) (Figure 
4c,d). EF and FS are the most commonly used indexes of left 
ventricle contractile function. EF represents the volumetric frac-
tion of blood pumped out of the left and right ventricle with each 
heartbeat, while FS measures the change in the diameter of the 
left ventricle between the contracted and relaxed cycles. After 
dobutamine stimulation, however, the EF (89.4 ± 5.1% for syn100 
promoter, 87.6 ± 5.3% for CB promoter) and FS (59.75 ± 6.0% for 
syn100 promoter, 57.09 ± 7% for CB promoter) of the AAV-treated 
homozygous mice were significantly higher than the untreated 
homozygous mice (80.9 ± 5.1% for EF, 49.0 ± 4.9% for FS, n = 
3–8, P < 0.05), and similar to the heterozygous control littermates 
(90.2 ± 5.5% for EF, 60.8 ± 8.2%) (Figure 4c,d). These results dem-
onstrated that the heart of the homozygous FKRP L276IKI mice 
indeed have compromised contractile capacity, and that overex-
pression of FKRP can completely restore original heart function.
DISCUSSION
Dystroglycanopathies have recently been recognized as the most 
common form of muscular dystrophies second to Duchenne mus-
cular dystrophy. FKRP-related dystroglycanopathies are associ-
ated with a wide range of muscular dystrophies from the most 
common, mild form of LGMD2I with adult onset to the rare but 
severe Walker-Warburg syndrome or muscle eye-brain disease 
with brain and eye involvement.3,18,20 Chan et al. 21 created a human 
FKRP mutation P448L knock-in mouse model P448LKI, which 
represents the severe congenital muscular dystrophies with early 
onset and with brain and eye involvement. Here, we described the 
FKRP L276IKI model with late onset and mild muscular dystro-
phic pathology reminiscent of the LGMD2I patients. The FKRP 
L276IKI model mimicked the LGMD2I pathology in nearly all 
aspects, including the major histopathology as well as the bio-
chemical deficiencies. Systemic gene delivery of FKRP in either 
neonatal mice or adult mice was able to achieve body wide FKRP 
gene expression and restoration of the α-dystroglycan glycosyl-
ation. Biochemical correction also resulted in histopathological 
correction for the homozygous FKRP L276IKI mice. Furthermore, 
both skeletal muscle and cardiac muscle functions were recovered 
as shown by the treadmill running distance and the echocardiog-
raphy results. Overexpression of FKRP did not reveal any discern-
able toxicity, suggesting gene therapy with FKRP gene replacement 
is a safe approach. Therefore, FKRP L276IKI represents a useful 
model that can be used to study the mechanisms of pathogenesis 
as well as new therapies in the most common form of LGMD.
The disease phenotype of the homozygous B6 FKRP L276IKI 
only slightly differed from that of the homozygous hybrid FKRP 
L276IKI. Only the serum CK level of homozygous B6 FKRP L276IKI 
was higher (Figure 1e) than the hybrid FKRP L276IKI (Figure 2e); 
therefore, minimal strain variations was indicated in this study. 
Furthermore, the mild FKRP L276IKI model of LGMD2I can 
also be converted into a more severe animal model by creating a 
compound heterozygous mutation line through breeding with a 
severe FKRP mouse line, which carries other missense mutations 
or a stop codon mutation. In human patients, some correlation 
between FKRP mutation and disease phenotype has been found.18 
For example, the L276I (C826A) mutation causes the mild pheno-
type LGMD2I, but the P448L mutation causes severe congenital 
muscular dystrophy. The homozygous P448LKI mouse model 
recreates the severe clinical phenotype.21 The compound hetero-
zygous mutation between the common L276I and either other 
missense mutations or a nonsense mutation causes the interme-
diate Duchenne-like severity; the compound heterozygous FKRP 
mutation between a nonsense mutation and a missense mutation 
or one that carries two missense mutations triggers the onset of the 
severe phenotype, with or without eye and brain involvement.18
In addition to the muscle pathology, cardiomyopathy is often 
found in LGMD2I patients.39,40 We also observed cardiac fibrosis 
and cell infiltration in the FKRP L276IKI model. However, echo-
cardiography did not detect any significant difference between 
the homozygotes and their heterozygous carrier control mice. No 
differences were found in the gene therapy treated mice either, 
despite overexpression of the FKRP gene in the heart. This phe-
nomenon brought to mind previous findings in the mdx mice, 
which also displayed cardiac fibrosis and cardiomyopathy, but 
echocardiography variations were insignificant until mice reached 
an older age.36 Nonetheless, the contractile function deficit of the 
mdx heart can be exacerbated becoming readily detectable when 
the cardiac stress test was induced by dobutamine treatment.36 
Similarly, the FKRP L276IKI mice also displayed significant cardiac 
function deficits by dobutamine-induced cardiac stress, as shown 
by the echocardiography (Figure 4). Gene therapy treated mice 
showed functional improvement compared to the heterozygous 
controls, suggesting efficient function recovery by FKRP overex-
pression without evidence of cardiac toxicity.
We did not see systemic toxicity associated with either AAV9-
CB-FKRP vector that contains a ubiquitous promoter or the AAV9-
Syn100-FKRP vector that contains a striated muscle-specific 
promoter. Furthermore, no additional functional improvements 
were observed between the syn100 promoter and the CB pro-
moter. Although the FKRP gene is expressed in many nonmuscle 
tissues,9 the liver and kidney functions were found to be normal in 
the mutant mice, which was verified by their normal serum ALT 
and BUN levels (Supplementary Figure S3). Understandably, a 
striated muscle-specific promoter is preferable for the purpose of 
systemic gene therapy. However, nonspecific expression of FKRP 
in the liver and the kidney was not found to cause any harm and 
could even provide beneficial effect to those tissues. Previously, 
overexpression of the LARGE gene induced hyperglycosylation of 
α-DG in skeletal and cardiac muscle causing toxicity.9 LARGE has 
a similar function to FKRP, since it phosphorylates the O-linked 
mannose on α-DG. Nevertheless, we did not observe similar 
hyperglycosylation effects associated with the overexpression of 
FKRP in our L276IKI model, suggesting FKRP gene therapy has a 
large safety margin and is an excellent approach for treating FKRP 
deficiency and other related dystroglycanopathties.
MATERIALS AND METHODS
Generation of the FKRP animal model and genotyping. The method used 
to create the knock-in mice was carefully described previously.21 Briefly, 
the FKRP KI mice were generated by the UNC core facility. The target-
ing vector was engineered with a c.826 C>A point mutation resulting in 
an amino acid change from leucine to isoleucine at position 276. The 
neomycin resistant (Neor) cassette was placed into intron 2 about 140 bp 
upstream from the coding exon 3. The PCR primers for genotyping the 
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heterozygous and homozygous mice were listed as follows: FKRP-WT-F: 
TTC TTG CCT CGG ATT GTG TAT G; FKRP-WT-R: TCA CTC TCC 
AAG GGC CTA CAG C; Neo-F-FKRP: AAC AAG ATG GAT TGC ACG 
CAG G; Neo-R-FKRP: TGG TCG AAT GGG CAG GTA G.
Plasmid construction and AAV vector production. The codon optimized 
human FKRP cDNA with myc tag fragments was synthesized from a com-
mercial company (GeneArt, Grand Island, NY). By digesting with restric-
tion enzymes, NotI and SalI, the cDNA fragments were cohesively ligated 
to the AAV backbone vector pXX-UF1, containing a CB promoter.41,42 
The final construct was named pXX-UF1-CB-FKRP-myc. Syn100 was 
based upon a synthetic muscle promoter (SP c5-12), which was screened 
from randomly assembled myogenic element libraries.35 To increase tis-
sue specificity and promoter strength, the downstream +100 bp sequence 
(cga gct acc cgg agg agc ggg agg cgt ctc tgc cag cgg tcc gac gcg cag tca gca 
cca ggt agg tgg gca ccg cgc cgt gcc gtg ccg tgc cgt gccg) of chicken skeletal 
α-actin promoter was added to the end of SP c5-12, and the new promoter 
was designated as syn100. To construct AAV vector plasmid containing 
syn100 promoter (pXX-UF1-syn100-FKRP), the PCR product of syn100 
promoter (flanked by KpnI and HpaI) was cloned into the KpnI and HpaI 
sites of pXX-UF1-CB-FKRP in order to replace the CB promoter.
AAV vectors were produced by triple transfection method43 and the 
virus was purified by polyethylene glycol (PEG) precipitation followed by 
CsCl centrifugation.44 The virus titer was determined by both dot-blot and 
real-time PCR methods.45,46 The concentration of the viral vectors was in 
the range of 2 × 1012 to 5 × 1012 vgs per milliliter (vg/ml).
Collagen staining and quantification. Two methods, Masson’s Trichrome 
staining and Sirius red/Fast green staining, were used for collagen display. 
The Masson trichrome stain kit was commercially available (IMEB, San 
Marcos, CA; cat# K7228), and the instructor’s protocol was strictly fol-
lowed. For Sirius red/Fast green staining, first, 10-μm cryo-section tissues 
were fixed with ice-cold acetone for 5 minutes. Following three repeated 
washings with tap water, the slides were then stained in 0.1% fast green 
for 15–20 minutes, and next in 0.1% Sirius red for 4 minutes. The stained 
slides were subjected to either dehydration and mounting for examination 
and pictures or elution for collagen quantification.
The collagen and noncollagen proteins were eluted from the stained 
slides using a dye extraction solution (a 1:1 mixture of 0.1 N NaOH and 
methanol) with gentle pipetting. Then, samples were quantified by protein 
measurement at wavelengths 540 and 605 nm. Formulas to calculate 
the collagen and total noncollagen protein are as follows: collagen (µg/
section) = (A540 nm−(A605 nm × 0.291))/37.8 × 1,000, where A540 nm and A605 nm 
are the absorbance at 540 and 605 nm, respectively; noncollagen protein 
(µg/section) = A605 nm/2.04 × 1,000. The ratio of collagen to noncollagen 
protein was presented in the Figures 1d and 3d.
Mice and vector administration. All protocols involving animal experi-
ments were approved by the University of North Carolina Animal Care 
and Use Committee. C57BL/6 mice were purchased from The Jackson 
Laboratory (Bar Harbor, ME). The L276I FKRP knock-in mice were gen-
erated and adapted from the UNC core facility. For systemic studies, the 
AAV serotype 9 FKRP vectors were delivered into the neonates (3–5 days 
old, 10 mice/group) of B6 background L276I FKRP KI mice by intraperi-
toneal injection (total 1 × 1011 vg/mouse).47 For adult injection, the vectors 
(6 × 1013 vg/kg) were delivered into the 9-month-old male mice through 
tail vein injection.
Immunofluorescent staining, western blot, and histology examination. 
The immunofluorescent staining was performed according to the previ-
ously published protocol.31,48 Since the anti-α-DG antibody (kindly pro-
vided by Dr Kevin P Campbell) was a monoclonal antibody (1:50 dilution), 
the mouse on mouse blocking reagent (VECTOR MKB-2213) was applied 
to the 8-µm cryo-section tissues right after the regular blocking procedure 
(with 10% horse serum) to prevent high background staining. For FKRP 
staining, the cryo-thin section tissues were fixed in 4% paraformaldehyde 
for 15 minutes. The rabbit polyclonal anti-FKRP antibody (raised against 
the last 15 residues of mouse FKRP sequence, NPE YPN PAL LSL TGG, 
kindly provide by Dr Lu’s laboratory) was used at 1:400 dilution. The rabbit 
polyclonal anti-myc antibody was from Abcam (Cambridge, MA; Catalog 
# ab9106). It was applied at 1:200 dilution. Photographs were taken with a 
Nikon Eclipse TE300 microscope, using a SPOT RT SLIDER digital cam-
era (Diagnostic Instrument, Life Technologies, Grand Island, NY).
The protocol of western blot against α-DG has been described 
previously.21 Briefly, the total proteins were dissolved in TX-100 buffer 
(1% Triton X-100, 50 mmol/l Tris, PH 8.0, 150 mmol/l NaCl, 0.1% sodium 
dodecyl sulfate (SDS)) supplemented with protease inhibitor cocktail 
(Sigma-Aldrich, St. Louis, MO). For the western blot against FKRP, 
total proteins were extracted from tissues of interest using lysis buffer 
containing 4% SDS, 125 mmol/l Tris PH 8.8, 4% glycerol, 100 mmol/l DTT 
(dithiothreitol), 0.01% BPB (bromophenol blue), and protease inhibitor 
cocktail. Protein concentration was determined by BCA protein assay kit 
(Pierce, Rockford, IL; Cat # 23227). Proteins (15 µg for each sample) were 
separated by 8–10% SDS–polyacrylamide gel electrophoresis (PAGE) and 
transferred to polyvinylidene fluoride membranes and probed with α-
DG antibody (1:1,000), or FKRP antibody (1:4,000), and developed with 
horseradish peroxidase–enhanced chemiluminescence.
H&E staining was performed for histology examination. In order to 
calculate the centrally located nuclei, three images (objective lens ×10) 
were taken from each muscle. All the fibers (roughly 1,000 fibers from 
each muscle) were counted from printed images.
Serum creatine kinase enzyme assay. Serum CK enzyme activities were 
measured with a creatine kinase reagent kit (Pointe Scientific, Canton, MI; 
catalog # C7512-120). The procedure was followed exactly according to the 
manufacturer’s instruction.
In vivo myofiber plasma membrane integrity test. Evans blue dye (10 mg/
ml phosphate-buffered saline) was injected into the tail vein of heterozy-
gous and homozygous FKRP L276I mice at the dose of 0.1 mg/g of body 
weight.25 After dye injection, mice were subjected to treadmill running 
(at a 15° downward angle at a rate of 15 m/minute) for 20 minutes. At 
16 hours after Evans blue injection, the mice were sacrificed and muscles 
were collected and cryo-sectioned. Evans blue dye-positive myofibers were 
observed under the fluorescent microscope with rhodamine filters.
Muscle function analysis. The fore limb grip force was performed using 
the digital force gauge (Chatillon Ametek, Largo, FL) as previously 
described.49 The treadmill tests were described in our previous study.28 
Briefly, both treated and nontreated mice were placed on a motorized 
treadmill (Harvard Apparatus, Holliston, MA; model 7054) to run at a 15° 
downward angle at a rate of 15 m/minute. The test was stopped after the 
animal spent 5 seconds sitting on the shock grid without attempting to 
re-enter the treadmill.
The in vitro contraction functional measurement was performed 
according to the previously published protocol, except for using a different 
model of transducer (Model 300B, dual mode; Aurora Scientific, Aurora, 
Ontario, Canada).48 Briefly, the TA muscle was isolated by removing the 
overlying bicep femoris and gently opening the fascia of the anterior 
compartment. The distal portion of the TA tendon was secured with a 4-0 
silk suture, and the entire TA was removed with its tibial origin intact. The 
TA tibial origin was fixed by securing the head of the tibia with a vascular 
clamp mounted in series to a micropositioner near the base of the tissue 
chamber. The tissue chamber was constantly perfused with mammalian 
Ringer’s solution aerated with 95% O2–5% CO2 and maintained at 25 °C. 
Care was taken to position the tibia in a vertical orientation so that the 
TA fibers were in vertical alignment. The muscle was stimulated by using 
the single pulse program (Stimulator model No 701A and A/D interface). 
Then, the muscle length was adjusted, and the muscle was restimulated 
with the single pulse program in order to find the optimal wave length and 
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maximal twitch force. Two minutes of resting time were given between 
stimulations. Tetanic force measurement and eccentric contraction testing 
were performed using fixed protocols specifically for tetanic stimulation 
and stretch stimulation. For tetanic force measurement, different 
stimulating frequencies (50, 75, 100, and 125 Hz) were utilized, and the 
maximal tetanic force (Po) was obtained. For eccentric contraction test 
(10 cycles), the specific value of individual muscle length was entered into 
the program to guarantee an accurate lengthening stretch. A 2-minute 
resting period was given between stimulation cycles. Following these 
measurements, the stimulated muscle was weighed on an analytic balance 
(Mettler Toledo, Columbia, MD; D521512), after the tendon and bone 
attachments were removed and the muscle was blotted dry. The specific 
tetanic forces (N/cm2) were calculated using the following formula: 





























Echocardiography. The echocardiography (Echo) analysis was described 
previously.38 Dobutamine was purchased from Sigma-Aldrich (catalog # 
D0676 -10MG). Experimental mice were sedated with 2.5% avertin (150 
ìl/10 g body weight). The freshly diluted dobutamine (2.25 µg/g body 
weight) was immediately injected into the mice via intraperitoneal deliv-
ery. The heart rate was increased by roughly 100 beats per minute after 
dobutamine stimulation. The second Echo was performed 2 minutes after 
dobutamine stimulation once the heart rate remained stable. The three 
M-mode graphs were saved for analysis from each Echo. There were three 
to eight mice involved in each group.
Statistical analysis. Values are expressed as means ± SD. Welch’s t-test was 
applied when comparing two groups. When comparing three groups, one-
way analysis of variance plus Dunnett post-test was applied using Graph 
Pad Prism software (GraphPad Software, La Jolla, CA). A P < 0.05 was 
considered statistically significant.
SUPPLEMENTARY MATERIAL
Figure S1. The muscle pathology of homozygous FKRP L276IKI mice 
was focal.
Figure S2. The muscle forces generated by homozygous FKRP L276IKI 
mice were weaker.
Figure S3. Serum ALT and BUN levels.
Figure S4. Expression of FKRP confirmed by anti-myc staining.
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